Pfizer Inc. (PFE) reported a 76 percent year-over-year operational adjusted earnings per share growth in its first quarter. Also, the company recorded 82% operational revenue growth overall and 2% operational growth excluding Comirnaty and Paxlovid. The company said its revenue growth was primarily driven by Comirnaty, Paxlovid, Prevnar family in U.S., Eliquis, Vyndaqel and Oncology Biosimilars in U.S.
First quarter adjusted EPS increased to $1.62 from $0.95, prior year. On average, 15 analysts polled by Thomson Reuters expected the company to report profit per share of $1.47, for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.